<html xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 11">
<meta name=Originator content="Microsoft Word 11">
<link rel=File-List href="hybrid%20nanoparticles_files/filelist.xml">
<title>Untitled Document</title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="country-region"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceName"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="PlaceType"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="State"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="City"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="place"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>ILPB User</o:Author>
  <o:LastAuthor>ILPB User</o:LastAuthor>
  <o:Revision>3</o:Revision>
  <o:TotalTime>15</o:TotalTime>
  <o:Created>2008-09-26T20:51:00Z</o:Created>
  <o:LastSaved>2008-09-26T21:12:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>923</o:Words>
  <o:Characters>5263</o:Characters>
  <o:Company>University at Buffalo</o:Company>
  <o:Lines>43</o:Lines>
  <o:Paragraphs>12</o:Paragraphs>
  <o:CharactersWithSpaces>6174</o:CharactersWithSpaces>
  <o:Version>11.9999</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" LatentStyleCount="156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]-->
</head>

<body lang=EN-US style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoNormal>Release Date 09/25/06 <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><st1:place w:st="on"><st1:City w:st="on">BUFFALO</st1:City>,
 <st1:State w:st="on">N.Y.</st1:State></st1:place> -- Since X-rays were
discovered more than a century ago, triggering a revolution in medical imaging,
clinicians have sought more powerful ways to &quot;see&quot; into the human
body. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>Now, with a $1.1 million grant from the John R. <span
class=SpellE>Oishei</span> Foundation, researchers in the University at <st1:City
w:st="on"><st1:place w:st="on">Buffalo</st1:place></st1:City>'s Institute for
Lasers, Photonics and <span class=SpellE>Biophotonics</span> are turning their
expertise in <span class=SpellE>nanomedicine</span> to the development of new, <span
class=SpellE>nanoparticle</span>-based multi-probe systems, launching a new
generation of medical imaging. The grant will fund research in which two or
more medical imaging techniques are combined to provide complementary
information. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>Part of a new field called <span class=SpellE><span
class=GramE>nanobiotechnology</span></span><span class=GramE>,</span> the UB
scientists are designing these <span class=SpellE>nanoparticle</span> systems
to contain multiple contrast agents for different imaging medical techniques. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The goal is to diagnose cancer and other diseases in their
earliest stages by providing far more comprehensive data to clinicians. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>&quot;Ultimately, clinicians want the most complete data
possible that they can gather from medical images, ranging from tissue
structure to metabolic processes to molecular markers,&quot; said <span
class=SpellE>Paras</span> Prasad, Ph.D., executive director of the Institute
for Lasers, Photonics and <span class=SpellE>Biophotonics</span> and SUNY
Distinguished Professor of Chemistry. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>&quot;We are aiming to provide them with such data by
developing <span class=SpellE>nanoparticle</span> platforms capable of carrying
multiple contrast agents for complementary medical imaging techniques in the
same <span class=SpellE>nano</span>-sized package,&quot; he said. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>Once injected with these multimodal <span class=SpellE>nanoparticles</span>,
the patient can undergo several imaging tests, the results of which will be
combined to provide more comprehensive and complementary information, such as
correlations between molecular and morphological changes at the cellular level.
<o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The result is a far more sensitive and comprehensive method
of detecting the presence or progression of a disease. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>&quot;At the same time, these imaging agents will provide
pharmaceutical researchers and clinicians with powerful tools for more precise
monitoring and tracking of drug action in real-time,&quot; said Prasad. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The multimodal platforms underway in Prasad's group are
based on versatile <span class=SpellE>nanoparticles</span> that the UB
researchers have developed with previous <span class=SpellE>Oishei</span>
Foundation funding that have been shown to be effective in a broad range of
therapeutic applications. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>&quot;The fields of <span class=SpellE>nanomedicine</span>
in which Dr. Prasad and his teams are working are developing extremely rapidly,
and they are at the forefront,&quot; said Thomas E. Baker, president of the
foundation. &quot;The work of these grants has tremendous potential for
significantly improving both the diagnostic capabilities of physicians and the
clinical outcomes of patients.&quot; <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The research also is being conducted with partial funding
from <span class=SpellE>UB's</span> New York State Center of Excellence in
Bioinformatics and Life Sciences, a major supporter of the <span class=SpellE>nanomedicine</span>
program at the Institute for Lasers, Photonics and <span class=SpellE>Biophotoncs</span>.
Prasad is affiliated with the Bioengineering/Tissue Engineering Team at the <st1:place
w:st="on"><st1:PlaceType w:st="on">Center</st1:PlaceType> of <st1:PlaceName
 w:st="on">Excellence</st1:PlaceName></st1:place>. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>&quot;This new imaging work represents an exciting and
timely extension of our existing <span class=SpellE>nanomedicine</span>
portfolio that will be particularly important for the <st1:PlaceType w:st="on">Center</st1:PlaceType>
of <st1:PlaceName w:st="on">Excellence</st1:PlaceName> initiatives in
neurodegenerative disease and cancer,&quot; said Bruce A. Holm, UB senior vice
provost and executive director of the <st1:place w:st="on"><st1:PlaceType
 w:st="on">Center</st1:PlaceType> of <st1:PlaceName w:st="on">Excellence</st1:PlaceName></st1:place>.
&quot;This research not only crosses a variety of UB 2020 Strategic Strength
areas, but holds enormous promise for commercialization potential as
well.&quot; <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The UB institute's new emphasis on application of <span
class=SpellE>nanobiotechnology</span> to medical imaging also distinguishes it
from other nanotechnology research centers throughout the <st1:country-region
w:st="on">U.S.</st1:country-region>, while enriching its current collaborations
with The Johns Hopkins University, <st1:City w:st="on"><st1:place w:st="on">Roswell</st1:place></st1:City>
Park Cancer Institute and others. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The <span class=SpellE>nanoprobes</span> are being developed
for use with: <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>-- Optical imaging techniques, especially those in which
fluorescence and Raman scattering can probe the intracellular distribution of
molecular events that are early signals of disease or responses to drugs <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>-- Magnetic resonance imaging (MRI), in which fluorine
nuclear probes would be developed using the <span class=SpellE>nanoparticles</span>,
providing more selective targeting of specific biological sites <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>-- Positron emission tomography (PET), in which
radioisotopes are incorporated inside <span class=SpellE>nanoparticles</span>
as contrast agents for more sensitive assessments of drug efficacy during
therapy <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>-- Computed tomography (CT) and single photon emission
computer tomography (SPECT), in which radio-opaque ions are incorporated inside
<span class=SpellE>nanoparticles</span> as contrast agents for improved in vivo
imaging. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The <span class=SpellE>Oishei</span> grant, &quot;Developing
New Advances in Medical Imaging through Nanotechnology,&quot; will be used in
part to recruit and support a research professor to provide expertise in
ultrasound imaging, as well as postdoctoral fellows and graduate students who
will focus on the development of multimodal <span class=SpellE>nanoprobes</span>
for medical imaging. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>In addition to Prasad, other key personnel involved in the
research from the Institute for Lasers, Photonics and <span class=SpellE>Biophotonics</span>
are E. J. <span class=SpellE>Bergey</span>, Ph.D., deputy director of <span
class=SpellE>biophotonics</span>; <span class=SpellE>Dinish</span> <span
class=SpellE>Sukumaran</span>, Ph.D., director of <span class=SpellE>UB's</span>
magnetic resonance center; <span class=SpellE>Indrajit</span> Roy, Ph.D.,
postdoctoral associate; <span class=SpellE>Tymish</span> Y. <span class=SpellE>Ohulchanskyy</span>,
Ph.D., postdoctoral associate; <span class=SpellE>Haridas</span> E. <span
class=SpellE>Pudivar</span>, Ph.D., research assistant professor and <span
class=SpellE>Aliksandr</span> <span class=SpellE>Kachynski</span>, Ph.D.,
research scholar, all in the Department of Chemistry. Also involved are Richard
V. <span class=SpellE>Mazurchuk</span>, Ph.D., director of the preclinical
magnetic resonance facility, <span class=SpellE>Ravindra</span> K. <span
class=SpellE>Pandey</span>, Ph.D., professor of biophysical sciences. Hani A. <span
class=SpellE>Nabi</span>, Ph.D., at Roswell Park Cancer Institute, and Benjamin
<span class=SpellE>Tsui</span>, Ph.D., at Johns Hopkins, also are involved. <o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>The John R. <span class=SpellE>Oishei</span> Foundation is
committed to enhancing the quality of life for Buffalo-area residents by
supporting education, health care, scientific research and the cultural,
social, civic and other charitable needs of the community. The foundation was
established in 1940 by John R. <span class=SpellE>Oishei</span>, founder of
Trico Products Corp., one of the world's leading manufacturers of windshield
wiper systems.</p>

</div>

</body>

</html>
